tbuckley/cabot-search huggingface dataset:
Model Liver
Authors: Tracy Hampton
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Calcium-antagonist (amlodipine) and atorvastatin synergy in inhibiting atherosclerosis in ApoE*3-Leiden mice. The CASSIA study Johan W. Jukema, Dianne J. M. Delsing, Arnoud van der Laarse, Hans van der Boom, Erik H. Offerman, Louis M. Havekes, Hans M. G. Princen. Leiden University Medical Center, Leiden, The Netherlands, TNO-PG Gaubius Laboratory, Leiden, The Netherlands
Journal: Journal of the American College of Cardiology (2001)
Narration: Timelessness
Authors: T S Danowski
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New hope for neurofibromatosis? The mast cell connection
Authors: H. N. Claman
Journal: JAMA (1987)

Neurofibromatosis is a common and progressive illness.<sup>1,2</sup>The spectrum of disease varies from the mildest of formes frustes to highly destructive and disfiguring syndromes. (It now seems that the most famous putative severe example, that of Joseph Merrick, "The Elephant Man," was not neurofibromatosis at all.<sup>3</sup>) The primary, if not the only, treatment has been surgery. In the August issue of the American Medical Association's<i>Archives of Dermatology</i>,<sup>4</sup>Riccardi presents his early experience in treating neurofibromatosis with ketotifen, a mast cell stabilizer.<sup>5</sup>During a three-year period, 15 patients received oral ketotifen. The conditions of 11 patients improved in one or more of the following variables: pain, itching, or the general feeling of well-being. In addition, most of these patients also had an apparent decrease in neurofibroma size, or a slowing of tumor growth, and a decrease in the profuse bleeding that accompanies surgery in this illness.
Arreiten Aus Dem Pharmazeutischen Institut Der Universitat Berlin.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HELIOTHERAPY AND RICKETS
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies
Authors: S. Cheng, M. Dietrich, S. Finnigan, A. Sandler, J. Crites, L. Ferranti, A. Wu, D. Dilts
Journal: Journal of Clinical Oncology (2009)

CRA6509 Background: Post-activation barriers to oncology clinical trial accruals are well documented; however, potential barriers prior to trial opening are not. We investigate one such barrier: trial development time. Methods: National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) sponsored trials for all therapeutic, non-pediatric phase I,I/II, II, and III studies activated in an eight year period (2000–2007) were investigated (n=553). Successful trials were those achieving 100% of minimum accrual goal. Time to open a study was the calendar time from initial CTEP submission to trialactivation. Multivariable logistic regression analysis was used tocalculate unadjusted and adjusted odds ratios, controlling for study phase and size of expected accruals. Results: 40.0 percent (n=221) of CTEP-approved oncology trials failed to achieve minimum accrual goals, with 49.2 percent (n=30) of phase III trials failing to achieve at least 25 percent of accrual goals. A total of 8,723 patients (17.0% of accruals) accrued to those studies that were unable to achieve the projected minimum accrual goal. Trials requiring 9–12 months development were significantly more likely to achieve accrual goals (odds ratio, 1.94; 95% CI, 1.06 to 3.52, P=0.031) than trials requiring the median time (15–18 months); trials that exceeded 27 months of development time were significantly less likely of achieving accrual goals (odds ratio, 0.14; 95% CI, 0.04 to 0.54, P=0.004). Conclusions: A large percentage of oncology clinical trials do not achieve minimum projected accruals. Trial development time appears to be one important predictor of the likelihood of successfully achieving the minimum accrual goals. [Table: see text] No significant financial relationships to disclose.
Thrombotic complications in a pediatric cardiovascular surgery population: A nine-year experience Therese M. Giglia, Dorothy I. Bulas, Jefferey E. Sell, Rebecca S. Chamberlain, Eric S. Quivers, Gail D. Pearson, Karl F. Gumpper, Frank M. Midgley, Gerard R. Martin, Naomi L. C. Luban. Children's National Medical Center, The George Washington University School of Medicine, Washington, DC
Journal: Journal of the American College of Cardiology (2001)
Urinary 6-oxo prostaglandin F1 alpha in myocardial infarction.
Authors: B R MacDonald, P B Jones, R G Russell, J Radford, J F Martin
Journal: BMJ (1983)

Urinary 6-oxo prostaglandin Fl. in myocardial infarctionPlatelet activity, which may play a part in both atherogenesis and thrombosis, is inhibited by prostacyclin in vitro.We report a study of urinary 6-oxo prostaglandin F,z, one of the stable prostacyclin metabolites, in myocardial infarction.Patients, methods, and results Eleven patients (mean age 57 9 years) with a diagnosis of myocardial infarction (classic history and electrocardiographic and enzyme changes) who denied having taken any drug for the previous 10 days gave an early morning two hour urine specimen after an overnight fast.Samples were collected on days 5 and 6, and eight to 10 weeks after myocardial infarction.Control samples were obtained under the same conditions from otherwise fit inpatients before operation who did not have the above diagnostic criteria.Family practitioners confirmed that no drug treatment was given after the patients' discharge from hospital.Prostaglandins were extracted from urine samples using octadecylsilyl silica C18 minicolumns and the prostanoid fraction eluted with methyl formate.
Should unpublished data be included in meta-analyses? Current convictions and controversies
Authors: D. J. Cook
Journal: JAMA (1993)

<h3>Objective.</h3> —To identify the extent to which meta-analyses currently include unpublished data and whether editors, meta-analysts, and methodologists believe unpublished material should be included. <h3>Design.</h3> —This article describes two related studies: a literature review and a cross-sectional survey. <h3>Sample Selection.</h3> —For the literature review, we identified all articles indexed by the key word meta-analysis from January 1989 to February 1991 and determined whether unpublished material had been searched for, obtained, and included in the meta-analyses. For the cross-sectional survey, we surveyed authors of these meta-analyses, authors of articles addressing methodological issues in metaanalysis published during the same period, and editors of journals in which both types of articles were published. <h3>Intervention.</h3> —We asked the respondents about their attitudes concerning inclusion of unpublished data and publication of articles from which data had previously been included in a scientific overview. <h3>Main Outcome Measures.</h3> —Inclusion of unpublished data and opinions about whether unpublished material should be included in overviews and whether prior inclusion of data in an overview should bear on publication. <h3>Results.</h3> —Of 150 meta-analyses, 46 (30.7%) included unpublished data in their primary analysis. Of authors surveyed, 85% responded. Of the meta-analysts and methodologists, 77.7% felt that unpublished material should definitely or probably be included in scientific overviews; this was true of 46.9% of the editors. A total of 86.4% of the meta-analysts and methodologists and 53.2% of the editors felt that inclusion of data in a prior overview should have no bearing on full publication of original research. <h3>Conclusion.</h3> —While inclusion of unpublished data in scientific overviews remains controversial, most investigators directly involved in meta-analysis believe that unpublished data should not be systematically excluded. The most valid synthesis of available information will result when meta-analysts subject published and unpublished material to the same rigorous methodological evaluation and present results with and without unpublished sources of data. (<i>JAMA</i>. 1993;269:2749-2753)
GW29-e0340 Low-level Transcutaneous Auricular Vagus Nerve Stimulation Induces Angiogenesis and Ameliorates Left Ventricular Dysfunction in a Rat Model of Chronic Myocardial Ischemia/Reperfusion Injury
Authors: Mingxian Chen, Lilei Yu, Xin Lai, Jianjun Tang, Qiming Liu, Shenghua Zhou
Journal: Journal of the American College of Cardiology (2018)
SIK2 Promotes Ovarian Cancer Spread
Journal: Cancer Discovery (2016)

A recent study reveals that the kinase SIK2 helps ovarian cancer cells metastasize and establish themselves in the fat-rich tissues of the abdominal cavity by promoting fatty-acid metabolism and cell proliferation. Mice bearing SIK2-overexpressing human ovarian cancer cells had larger, more abundant metastases than those whose tumors bore an inactive form of the kinase.
Internal medicine
Authors: S. A. Wartman
Journal: JAMA (1990)

Several important trends suggest that the 1990s will prove to be a critical decade for internal medicine. Recent data that involve the practice of general internal medicine indicate that general internists are experiencing some changes in practice patterns. More care is being provided in the ambulatory setting as internists are making fewer hospital visits and seeing more patients in the office.<sup>1</sup>Those patients who are admitted to the hospital tend to be very ill, older, or decompensating because of a previously diagnosed disease or are undergoing a specific procedure. Office patients, on the other hand, tend to need diagnostic efforts, chronic disease follow-up, and management of psychosocial dysfunction. In addition, increasing emphasis on preventive care and health maintenance requires internists to spend more time talking with and educating their patients. These changing practice patterns have pragmatic implications such as how internists may set up and staff their offices. They
Breast cancer incidence in a large cohort of Peruvian women affiliated to a pre-paid system.
Authors: Juan F. Suazo, Priscila I. Valdiviezo, Claudio J. Flores, Jorge Iberico, Joseph A. Pinto, Alfredo Aguilar, Carlos Enrique Vigil, Henry Gomez, Carlos S. Vallejos
Journal: Journal of Clinical Oncology (2013)

e12570 Background: Breast cancer (BC) is the second most common malignancy and the leading cause of death by cancer in Peruvian women (age-standarized rate [ASR] of 34 new cases/100,000 women estimated by GLOBOCAN 2008). The purpose of this study was to assess the incidence of BCin acohort ofwomenat Oncosalud, an oncologic pre-paid system that currently has 600,000 affiliates. Methods: We evaluated a dynamic cohort (period 1989 to 2011) of women affiliatedat Oncosalud – AUNA, an oncologic prepaid system.The crude incidence rate per year (number of new cases/women at risk), the specific rate according to age (number of new cases / persons-year) and cumulative risk were calculated. Results: Overall, during the assessment period, the BC incidence rate per year was 175.6 and the ASR incidence was 111.9 per 100,000 affiliates respectively. In our cohort of affiliates there were no BC cases before 1993 (with 907 women at risk for that year). The highest incidence rate was 177.6 registered in 1997 (11,822 women at risk). Incidence rates started decreasing in 2003 (169.2 with a population at risk of 39,593 women). The lowest incidence was 71.5, registered in 2011 (279,680 women at risk).According to age-groups, there were no BC cases under20 years old. Specificincidence ratesper age-group increases from the 30 year old-group (55.8). The peak of BC incidence was between 70 to 74 years old (407.4). In the same way, the cumulative risk increases after 30 years old. Conclusions: In our cohort of affiliates, the incidence of BC is greater than the general population, it could be due to the process of negative selection; however, specific incidence rates per age-group and cumulative risk are increased after 30 years, as seen in the general population.
MEDICAL SUPERVISION IN THE INDUSTRIAL WORLD
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ABOUT-24-HOURS RHYTHMS
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HLA DPB Polymorphism in primary sclerosing cholangitis and primary biliary cirrhosis
Authors: J UNDERHILL
Journal: Hepatology (1995)

In recent years there has been an increasing interest in the link between susceptibility to autoimmune liver disease and genes of the HLA system, although the role of the DPB1 locus in British patients has only been investigated in autoimmune hepatitis. The aim of the current study was to determine the distribution of DPB1 alleles in a large series of British patients with the two other autoimmune liver diseases, primary biliary cirrhosis and primary sclerosing cholangitis, and compare the allele frequencies obtained with those of a geographically matched control group. Polymerase chain reaction sequence-specific oligonucleotide probing was used to assign 18 DPB1 alleles in 82 patients with primary biliary cirrhosis (PBC), 71 patients with primary sclerosing cholangitis (PSC), and 103 controls. The frequencies of the DPB1 alleles were not significantly different comparing patients and controls. However, two important observations were made. Firstly, in primary sclerosing cholangitis, the previously reported association with the haplotype A1-B8-DR3-DQ2 does not extend to the DPB1 locus, suggesting that the genetic determinants of susceptibility for this disease lie closer to the DRB loci. Secondly, in primary biliary cirrhosis there is evidence that the reported association with DR8-DQB1*0402 includes the DPB1*0301 allele. The weak HLA association reported here is in contrast with recent data from Japan, where susceptibility is strongly linked to a particular amino acid residue encoded by the DPB1*0501 allele. These data clearly demonstrate that the alleles of the DPB1 locus are not associated with susceptibility to or protection from either primary biliary cirrhosis or primary sclerosing cholangitis in British patients. (HEPATOLOGY 1995; 21:959–962.)
High plasma 25-hydroxyvitamin D and high risk of nonmelanoma skin cancer: a Mendelian randomization study of 97 849 individuals
Authors: U.C. Winsløw, B.G. Nordestgaard, S. Afzal
Journal: British Journal of Dermatology (2018)

In this study from Denmark, we investigate whether vitamin D status, usually measured by 25‐hydroxyvitamin D in blood samples, is associated with development of non‐melanoma skin cancer (NMSC). Previously, it has proven difficult to answer this particular question. If you simply divide everyone into two groups, i.e. those with a high and those with low measured 25‐hydroxyvitamin D, a higher incidence rate of NMSC would be observed in the group with high 25‐hydroxyvitamin D. However, this simple observation is susceptible to misinterpretation, e.g. sunlight's UV radiation causes damage to the skin that starts the development of skin cancer, as well as inducing vitamin D synthesis in the skin (i.e. helping the body to create vitamin D). On average, people who have higher high 25‐hydroxyvitamin D levels will therefore also have been exposed to more sunlight and UV radiation and be at higher risk of developing skin cancer. For this reason, we could observe a potentially false association between 25‐hydroxyvitamin D and cancer if we base our conclusions on just raw data alone. In this study, we used a method called Mendelian randomisation that is not susceptible to these potential errors, and we found that genetic variants affecting vitamin D neither increase nor decrease the risk of getting skin cancer. The implications of this study are that the association of 25‐hydroxyvitamin D with skin cancer cannot be taken at face value and similar studies are required for other types of cancer.